Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen vs Aspirin in Coronary Atherosclerosis
NCT05105750Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Indobufen in Coronary atherosclerosis (CAD) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Maximum Platelet Aggregation at 1 month, Plasma Thromboxane B2 at 1 month and 1 more. Status: unknown.
02
Drugs
Indobufen
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT05105750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105750.